These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22131268)

  • 1. Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage.
    Yuen B; Boncompagni S; Feng W; Yang T; Lopez JR; Matthaei KI; Goth SR; Protasi F; Franzini-Armstrong C; Allen PD; Pessah IN
    FASEB J; 2012 Mar; 26(3):1311-22. PubMed ID: 22131268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene dose influences cellular and calcium channel dysregulation in heterozygous and homozygous T4826I-RYR1 malignant hyperthermia-susceptible muscle.
    Barrientos GC; Feng W; Truong K; Matthaei KI; Yang T; Allen PD; Lopez JR; Pessah IN
    J Biol Chem; 2012 Jan; 287(4):2863-76. PubMed ID: 22139840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1.
    Lopez JR; Kaura V; Diggle CP; Hopkins PM; Allen PD
    Br J Anaesth; 2018 Oct; 121(4):953-961. PubMed ID: 30236258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative malignant hyperthermia mutation Ca
    Feng W; Lopez JR; Antrobus S; Zheng J; Uryash A; Dong Y; Beqollari D; Bannister RA; Hopkins PM; Beam KG; Allen PD; Pessah IN
    J Biol Chem; 2023 Aug; 299(8):104992. PubMed ID: 37392848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Chlorantraniliprole and Flubendiamide Activity Toward Wild-Type and Malignant Hyperthermia-Susceptible Ryanodine Receptors and Heat Stress Intolerance.
    Truong KM; Pessah IN
    Toxicol Sci; 2019 Feb; 167(2):509-523. PubMed ID: 30329129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A malignant hyperthermia-inducing mutation in RYR1 (R163C): alterations in Ca2+ entry, release, and retrograde signaling to the DHPR.
    Estève E; Eltit JM; Bannister RA; Liu K; Pessah IN; Beam KG; Allen PD; López JR
    J Gen Physiol; 2010 Jun; 135(6):619-28. PubMed ID: 20479110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary Caffeine Synergizes Adverse Peripheral and Central Responses to Anesthesia in Malignant Hyperthermia Susceptible Mice.
    Aleman M; Zhang R; Feng W; Qi L; Lopez JR; Crowe C; Dong Y; Cherednichenko G; Pessah IN
    Mol Pharmacol; 2020 Oct; 98(4):351-363. PubMed ID: 32764093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
    Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
    Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A malignant hyperthermia-inducing mutation in RYR1 (R163C): consequent alterations in the functional properties of DHPR channels.
    Bannister RA; Estève E; Eltit JM; Pessah IN; Allen PD; López JR; Beam KG
    J Gen Physiol; 2010 Jun; 135(6):629-40. PubMed ID: 20479108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.
    Chelu MG; Goonasekera SA; Durham WJ; Tang W; Lueck JD; Riehl J; Pessah IN; Zhang P; Bhattacharjee MB; Dirksen RT; Hamilton SL
    FASEB J; 2006 Feb; 20(2):329-30. PubMed ID: 16284304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal bioenergetic abnormalities in skeletal muscle from ryanodine receptor malignant hyperthermia-susceptible R163C knock-in mice.
    Giulivi C; Ross-Inta C; Omanska-Klusek A; Napoli E; Sakaguchi D; Barrientos G; Allen PD; Pessah IN
    J Biol Chem; 2011 Jan; 286(1):99-113. PubMed ID: 20978128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and biochemical properties of ryanodine receptor type 1 channels from heterozygous R163C malignant hyperthermia-susceptible mice.
    Feng W; Barrientos GC; Cherednichenko G; Yang T; Padilla IT; Truong K; Allen PD; Lopez JR; Pessah IN
    Mol Pharmacol; 2011 Mar; 79(3):420-31. PubMed ID: 21156754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse.
    Yang T; Riehl J; Esteve E; Matthaei KI; Goth S; Allen PD; Pessah IN; Lopez JR
    Anesthesiology; 2006 Dec; 105(6):1164-75. PubMed ID: 17122579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
    Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
    Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling.
    Yang T; Ta TA; Pessah IN; Allen PD
    J Biol Chem; 2003 Jul; 278(28):25722-30. PubMed ID: 12732639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
    Girard T; Treves S; Censier K; Mueller CR; Zorzato F; Urwyler A
    Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
    Eltit JM; Bannister RA; Moua O; Altamirano F; Hopkins PM; Pessah IN; Molinski TF; López JR; Beam KG; Allen PD
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7923-8. PubMed ID: 22547813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.